[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346168-105":59,"doc-detail-346168-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","cancer-patients-mortality-from-other-causes-a-european-population-based-study","Cancer Patients Mortality From Other Causes - A European Population-Based Study","","Cancer patients face elevated mortality driven not only by the index malignancy but also by multi-morbidity and treatment-related complications. This European population-based analysis examines all-cause deaths excluding the index cancer, contrasting cancer patients with the general population. Using EUROCARE-6 data (1998–2013; follow-up to 31 December 2014), relative risks and cause-specific versus relative survival are assessed at 5 and 10 years, highlighting age patterns and cancer-type differences.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cancer-patients-mortality-from-other-causes-a-european-population-based-study/346168/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cancer-patients-mortality-from-other-causes-a-european-population-based-study/346168.png","ImageObject",300,407,{"name":92,"@type":93},"Ophelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What question does the study address about cancer patients’ deaths?","Question",{"text":113,"@type":114},"It examines mortality from all causes other than the index cancer among cancer patients, compared with the general population.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which dataset and population were used?",{"text":118,"@type":114},"The analysis uses EUROCARE-6 data on 1,894,057 cancers diagnosed across 13 European countries, collected by 17 cancer registries with official cause-of-death information.",{"name":120,"@type":111,"acceptedAnswer":121},"What key survival comparisons were reported?",{"text":122,"@type":114},"Cause-specific survival (CSS) is compared to relative survival (RS) at 5 and 10 years, with CSS exceeding RS in several cancer types and being lower in breast and prostate cancers.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},346168,1790418775,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Cancer Medicine  \nRESEARCH ARTICLE  OPEN ACCESS   \nCancer Patients Mortality From Other Causes: A European Population-Based Study  \nGemma Gatta1  | Riccardo Capocaccia2  | Silvia Rossi3  | Maria Athanasiadou4 | Damien Bennett5  | Ladislav Dusek6  | Jaume Galceran7  | Monica Hackl8 | Bernd Holleczek9  | Kaire Innos10  |  \nAlexander Katalinic11  | Raphael Marcos-Gragera12  | Deirdre Murray13  | Robin Schaffar14  | Stephanie Smits15  | Giedrė Smailytė16  | Hans Storm17  | Claudia Vener18  | Tina Žagar19  | Alice Bernasconi18  |  \nValerie Jooste20,21,22,23  | Laura Botta18  | the EUROCARE-6 WG  \n1Università Milano Bicocca, Milan, Italy | 2Editorial Board, Epidemiologia e Prevenzione, Milan, Italy | 3Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy | 4Cyprus Ministry of Health, Nicosia, Cyprus | 5Northern Ireland Cancer Registry, Queen's University Belfast, Belfast, UK | 6Biostatistics and Analysis Institute, Masarykova University, Brno, Czech Republic | 7Epidemiology and Prevention Cancer Service, Hospital Universitari Sant Joan de Reus, IISPV, Reus, Spain | 8Austrian National Cancer Registry, Wien, Austria | 9Saarland Cancer Registry, Saarbrücken, Germany | 10National Institute for Health Development, Tallin, Estonia | 11Institute of Social Medicine and Epidemiology, University of Lubeck, Lübeck, Germany | 12Girona Cancer Registry, Catalan Institute of Oncology, Girona, Spain | 13National Cancer Registry Ireland and Department of Public Health, University College Cork, Cork, Ireland | 14Geneva Cancer Registry, Institute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland | 15Welsh Cancer Intelligence and Surveillance Unit, Public Health Wales, Cardiff, UK | 16Lithuania National CR, Institute of Oncology, Vilnius University, Vilnius, Lithuania | 17Danish Cancer Society, Copenhagen, Denmark | 18Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy | 19Slovenian Cancer Registry, Institute of Oncology Ljubljana, Ljubljana, Slovenia | 20Digestive Cancer Registry of Burgundy Dijon, Dijon, France | 21Centre Hospitalier Universitaire (CHU) Dijon Bourgogne, Dijon, France | 22CTM Research Center—  \nUMR1231, Institut National de la Santé et de la Recherche Médicale (INSERM), Dijon, France | 23Université Bourgogne Europe, Dijon, France Correspondence: Riccardo Capocaccia ([capocaccia.riccardo@gmail.com](capocaccia.riccardo@gmail.com))  \nReceived: 3 February 2026 | Revised: 1 August 2026 | Accepted: 2 September 2026  \nABSTRACT  \nIntroduction: Cancer patients may face elevated mortality not only from their malignancy but also from other factors including multi-morbidity and the impact of treatment-related complications. This study analyses mortality from all causes other than the index cancer among cancer patients compared to the general population.  \nMethods: We analysed EUROCARE-6 data on 1,894,057 cancers diagnosed in 13 European countries and collected by 17 cancer registries with complete official cause-of-death information. Included were first-primary head and neck (H&N), stomach, colorectal, lung, breast, cervical, endometrial, ovarian, prostatic, kidney, and bladder cancers diagnosed between 1998 and 2013 in patients aged 15–79, with follow-up until 31st December 2014. We estimated the relative risk (RR) of death from all other causes for patients relative to population mortality rates. Cause-specific survival (CSS) was compared to relative survival (RS) at 5 and 10 years.  \nResults: RR were >2 for H&N and female lung cancers, between 1 and 2 for stomach, male lung, cervix, endometrial, ovary, kidney and bladder, and \u003C 1 for prostate and female breast cancers. Relative risk declined with increasing age for almost all cancer types. Ten-year CSS exceeded RS by 7%–11% points (pp) in H&N cancers, with smaller differences in bladder (2–6 pp), stomach, lung, cervix, ovary and kidney (2–3 pp) . CSS was lower than RS in breast and pros","cbCaibBvzPxdCF0a","https://ap.wps.com/l/cbCaibBvzPxdCF0a","pdf",837832,"English","# Abstract\n## Introduction\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What question does the study address about cancer patients’ deaths?\",\"answer\":\"It examines mortality from all causes other than the index cancer among cancer patients, compared with the general population.\"},{\"question\":\"Which dataset and population were used?\",\"answer\":\"The analysis uses EUROCARE-6 data on 1,894,057 cancers diagnosed across 13 European countries, collected by 17 cancer registries with official cause-of-death information.\"},{\"question\":\"What key survival comparisons were reported?\",\"answer\":\"Cause-specific survival (CSS) is compared to relative survival (RS) at 5 and 10 years, with CSS exceeding RS in several cancer types and being lower in breast and prostate cancers.\"}]","Cancer Patients Mortality From Other Causes - A European Population-Based Study | PDF",1790060367,25,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f0b8668615b7ddec533b58d6a83f2d72.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/de9f2209d45b0d75b85a93f3fd949552.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/958ee5176b564b4d648fe7a54fbf1182.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/93da62c794b5a2f1d6271c9b2f81b636.webp",980,1287]